EDETOX logo

IN VIVO STUDIES FURTHER DETAILS

In Vivo Study No: 594

METHODS

Chemical	Membrane	Concentration mg/ml	Concentration mg/ml	loading (mg/cm2)	Species	Site	Area (cm2)	Occluded?	Exposure Time (h)	Analytical Method
Isofenphos	0.06	2.64	0.0132	Acetone	Human	Ventral Forearm	12	2	72	Radiolabelled (14C)

RESULTS

Length of Study (h)	% Recovery	+/-	Dose remaining on surface (mg)	% remaining on Surface	Dose remaining in stratum corneum (mg)	% remaining in stratum corneum	Dose remaining in the viable skin	% remaining in the viable skin	Amount Absorbed (mg)	% Absorbed	+/-	% Absorbed
168			0.0005	0.31					0.0058	3.64	0.48	3.64

Length of Study (h)

% Recovery

+/-

Dose remaining on surface (mg)

% remaining on Surface

Dose remaining in stratum corneum (mg)

% remaining in stratum corneum

Dose remaining in the viable skin

% remaining in the viable skin

Amount Absorbed (mg)

% Absorbed

+/-

% Absorbed

168

0.0005

0.31

0.0058

3.64

0.48

3.64

Maximal Flux (mcrg/cm2/h)	Average Flux (mcrg/cm2/h)	+/-	Time Plasma/Blood Levels Peaked (h)	Peak Blood Concentration (mg/l)	n	kp (cm/h)	Lag Time (h)
					4

NOTES

The dose was allowed to dry on the skin (5 min) and then the volunteers were allowed to cover the application site with clothing. The dose site was washed at 72h. The skin was stripped after 7-days to calculate the amount retained in the Stratum Corneum. An IV dose was given to Rhesus Monkeys and the amount excreted in the urine after 7 days was calculated this was then used to correct for incomplete excretion in the urine by man to give the % absorption. The % recovery was extremely low.

REFERENCE

In Vivo And In Vitro Percutaneous Absorption And Skin Evaporation Of Isofenphos In Man (1992) Fundam. Appl. Toxicol., 19 :521-526